Beranda › PPOK › Alabama › Mobile
Uji klinis PPOK di Mobile, AL
4 studi untuk PPOK mencari peserta di lokasi sekitar Mobile (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
Menerima pesertaFase 3
- Research Site, Mobile
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
Menerima pesertaFase 3
- Pulmonary Associates - Mobile- Site Number : 8400151, Mobile
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
Menerima pesertaFase 3
- Research Site, Mobile
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
Menerima pesertaFase 2/3
- Pulmonary Associates of Mobile, P.C., Mobile
Uji klinis PPOK di kota lain
- Philadelphia, PA23 studi
- Miami, FL18 studi
- Birmingham, AL17 studi
- Boston, MA17 studi
- Orlando, FL15 studi
- Houston, TX15 studi
- Baltimore, MD14 studi
- Chicago, IL14 studi
- Dallas, TX12 studi
- Pittsburgh, PA12 studi
- New York City, NY11 studi
- Ann Arbor, MI10 studi
Studi lain di Mobile
- Kanker Paru Non-Sel Kecil13 studi
- Gagal Jantung13 studi
- Kanker Paru7 studi
- Kanker Payudara7 studi
- Kanker Ovarium7 studi
- Obesitas7 studi
- Kanker (semua jenis)6 studi
- Melanoma6 studi
- Kanker Paru Sel Kecil6 studi
- Penyakit Kardiovaskular6 studi
- Fibrilasi Atrium5 studi
- Kelebihan Berat Badan5 studi
Dari ClinicalTrials.gov, data diambil 3 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.